Juzimette (Metformin Hydrochloride, Sitagliptin)

Metformin decreases the liver’s production of glucose and improves the body’s response to insulin, while sitagliptin blocks the enzyme DPP‑4, raising levels of incretin hormones that stimulate insulin release only when blood glucose is high. Together they provide complementary glucose‑lowering effects.

The dosage of Juzimette is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Physicians determine the appropriate strength and frequency, and patients should follow the prescriber’s instructions exactly.

Safety of Juzimette during pregnancy or lactation has not been definitively established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order Juzimette, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with single‑agent therapies, Juzimette offers a fixed‑dose combination that targets two different pathways, often providing greater HbA1c reduction than metformin alone. It may be preferred over separate tablets for convenience, but clinicians consider individual patient factors when choosing between combination products or other drug classes.

Juzimette tablets should be stored at ambient temperature, preferably below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date printed on the packaging.

Juzimette is taken orally, usually once daily with or without food, as directed by the prescriber. Swallow the tablet whole with a full glass of water; do not crush or chew it unless specifically instructed by a healthcare professional.

The most serious adverse events to monitor are lactic acidosis, which can be life‑threatening, acute pancreatitis, and severe skin reactions such as Stevens‑Johnson syndrome. Prompt medical attention is required if patients experience unexplained muscle pain, abdominal pain, or widespread rash.

Juzimette is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, or a history of lactic acidosis. Caution is also advised for individuals with significant liver disease, heart failure, or uncontrolled heart conditions.